Elite Pharmaceuticals, Inc.
ELTP
$0.37
$0.00-0.62%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 27.35% | 119.92% | 92.38% | 113.85% | 78.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.35% | 119.92% | 92.38% | 113.85% | 78.26% |
| Cost of Revenue | 35.88% | 126.03% | 108.26% | 25.72% | 49.54% |
| Gross Profit | 20.10% | 111.68% | 71.68% | 221.26% | 113.04% |
| SG&A Expenses | 270.26% | -10.15% | 75.36% | 70.98% | -8.93% |
| Depreciation & Amortization | -9.73% | -10.27% | -6.04% | -7.24% | 7.61% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.45% | 70.18% | 82.57% | 23.91% | 35.29% |
| Operating Income | -13.51% | 721.00% | 135.69% | 461.57% | 242.14% |
| Income Before Tax | 8.21% | 295.57% | 264.83% | -166.55% | 866.79% |
| Income Tax Expenses | 5.24% | 836.41% | 31.02% | 2,193.32% | 270.67% |
| Earnings from Continuing Operations | 8.61% | 270.71% | 224.16% | -1,055.62% | 411.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.61% | 270.71% | 224.16% | -1,055.62% | 411.07% |
| EBIT | -13.51% | 721.00% | 135.69% | 461.57% | 242.14% |
| EBITDA | -13.39% | 514.33% | 120.43% | 415.05% | 221.42% |
| EPS Basic | 7.55% | 269.61% | 224.27% | -1,016.67% | 381.82% |
| Normalized Basic EPS | 3.28% | 295.16% | 262.50% | -160.00% | 916.67% |
| EPS Diluted | -37.74% | 157.84% | 152.43% | -1,766.67% | 15,800.00% |
| Normalized Diluted EPS | -6.56% | 283.87% | 253.57% | -160.00% | 916.67% |
| Average Basic Shares Outstanding | 0.79% | 0.55% | 0.34% | 0.01% | 4.84% |
| Average Diluted Shares Outstanding | 11.28% | 6.80% | 6.86% | -0.73% | 3.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |